Académique Documents
Professionnel Documents
Culture Documents
(cel-e-cox'ib)
Celebrex
Classifications: CENTRAL NERVOUS SYSTEM AGENT, ANALGESIC, NSAID,
CYCLOOXYGENASE-2 INHIBITOR, ANTIPYRETIC
Pregnancy Category: C first and second trimesters; D third trimester
Availability
100 mg, 200 mg, 400 mg capsules
Actions
NSAID that exhibits antiinflammatory, analgesic, and antipyretic activities. Unlike
ibuprofen, inhibits prostaglandin synthesis by inhibiting cyclooxygenase-2 (COX-2), but
does not inhibit cyclooxygenase-1 (COX-1).
Therapeutic Effects
Reduces or eliminates the pain of rheumatoid and osteoarthritis.
Uses
Relief of S&S of osteoarthritis and rheumatoid arthritis. Treatment of acute pain and
primary dysmenorrhea. Reduction of polyp formation in Familial Adenomatous
Polyposis (FAP)
Contraindications
Severe hepatic impairment; hypersensitivity to celecoxib; asthmatic patients with aspirin
triad; advanced renal disease; concurrent use of diuretics and ACE inhibitors; anemia;
pregnancy (category D) in third trimester; lactation.
Cautious Use
Patients who are P450 2C9 poor metabolizers; patients who weigh <50 kg; moderate
hepatic impairment; renal insufficiency; aspirin use; prior history of GI bleeding or peptic
ulcer disease; asthmatics; pregnancy (category C) in first and second trimesters, and
(category D) in third trimester; elevated liver function tests; heart failure; kidney disease;
hypertension; fluid retention.
Arthritis
Adult: PO 100–200 mg b.i.d. or 200 mg q.d.
FAP
Adult: PO 400 mg b.i.d.
Administration
Oral
Interactions
Drug: May diminish effectiveness of ACE INHIBITORS; fluconazole increases celecoxib
concentrations; may increase lithium concentrations; may increase INR in older patients
on warfarin.
Pharmacokinetics
Peak: 3 h. Distribution: 97% protein bound; crosses placenta. Metabolism: Metabolized
in liver by cytochrome P450 2C9 enzymes. Elimination: Excreted primarily in feces
(57%), 27% excreted in urine. Half-Life: 11.2 h.
NURSING IMPLICATIONS
Assessment & Drug Effects
Common adverse effects in italic, life-threatening effects underlined: generic names in bold; classifications
in SMALL CAPS; Canadian drug name; Prototype drug